WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014204898) USE OF IL-20 ANTAGONISTS FOR ALLEVIATING OBESITY
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/204898 International Application No.: PCT/US2014/042634
Publication Date: 24.12.2014 International Filing Date: 17.06.2014
IPC:
A61K 39/395 (2006.01) ,A61P 3/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
Applicants: NATIONAL CHENG KUNG UNIVERSITY; No. 1, University Road Tainan City, 701, TW
Inventors: CHANG, Ming-Shi; TW
HSU, Yu-Hsiang; TW
Agent: CHEN, Yahua; US
Priority Data:
61/835,80617.06.2013US
Title (EN) USE OF IL-20 ANTAGONISTS FOR ALLEVIATING OBESITY
(FR) UTILISATION D'ANTAGONISTES D'IL -20 POUR RÉDUIRE L'OBÉSITÉ
Abstract:
(EN) Alleviating obesity in a subject (e.g., a human subject) having, being suspected of having, or at risk for obesity using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.
(FR) La présente invention a pour objet de réduire l'obésité chez un sujet (par exemple, un sujet humain) qui est obèse, qui est présumé obèse ou qui présente un risque d'obésité, au moyen d'un antagoniste d'IL -20, qui peut être un anticorps qui bloque une voie de signalisation médiée par IL -20. De tels anticorps comprennent des anticorps anti-IL -20 et anti-IL -20 R anticorps qui bloquent spécifiquement la voie de signalisation IL -20.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)